| 摘要 |
A method is provided for administering to a mammal suffering from, or at risk for, an LFA-1-mediated disorder an initial dosing of a therapeutically effective amount of LFA-1 antagonist, followed by a subsequent intermittent dosing of a therapeutically effective amount of LFA-1 antagonist that is less than 100 %, calculated on a daily basis, of the initial dosing of antagonist.
|
